Improve Bleeding Control for Cardiac Patients

[upamfva]

Improve Bleeding Control for Cardiac Patients


At UPMC in Central Pa., cardiovascular experts are studying the safety and effectiveness of the QuikClot Control+® hemostatic dressing compared to standard gauze in cardiac surgery patients who experience mild to moderate bleeding. Previous animal studies have found that the QuikClot Control+® hemostatic dressing is effective in treating class III or IV bleeding – the hemostatic dressing was the first to be FDA-cleared for severe bleeding in the internal organ space. To get more news about IFAK, you can visit rusuntacmed.com official website.

Cardiovascular disease remains the leading cause of death in the United States. To improve outcomes of these procedures, it is critical for surgeons to have a hemostatic device that quickly minimizes blood loss and can be easily applied. The QuikClot Control+® is a kaolin-based dressing which has shown to be more effective at hemorrhage control than standard laparotomy sponges in a previous clinical trial.1
The primary efficacy endpoint of this multicenter, prospective, randomized, controlled cardiac IDE study is to evaluate the rate at which 231 patients achieved hemostasis through 10 minutes of hemostatic application and compression at the site of hemorrhage. The proportion of subjects achieving hemostasis measured at 5 and 10 minutes will also be recorded.

Mubashir A. Mumtaz, MD, chief of cardiothoracic surgery and surgical director of the structural heart program at UPMC in Central Pa., is the national principal investigator of this multicenter trial. He has extensive experience with a wide range of adult cardiac procedures including repair, reconstruction or replacement of the heart valves using native tissue, robotic and conventional coronary bypass grafting, and thoracic aortic surgeries.

“As part of our humanitarian efforts, we are constantly trying to improve patient experience. We are therefore seeking the latest technology to improve outcomes, shorten hospital times, and lessen pain for cardiac patients in Central Pennsylvania and beyond.”